An RCT of ganciclovir prophylaxis for CMV disease in pediatric liver transplant recipients.

被引：0
|
作者：
King, SM
Superina, R
Andrews, W
Winston, D
Dunn, S
Colombani, P
机构：
[1] HOSP SICK CHILDREN,TORONTO,ON M5G 1X8,CANADA
[2] SW MED CTR,DALLAS,TX
[3] UNIV CALIF LOS ANGELES,LOS ANGELES,CA
[4] ST CHRISTOPHERS HOSP,PHILADELPHIA,PA
[5] JOHNS HOPKINS UNIV,BALTIMORE,MD
来源：
CLINICAL INFECTIOUS DISEASES | 1996年 / 23卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：243 / 243
页数：1
相关论文
共 50 条
  • [1] Oral ganciclovir prophylaxis of cytomegalovirus (CMV) disease in pediatric renal transplant recipients.
    Feneberg, R
    Weber, LT
    Fickenscher, H
    Toenshoff, B
    PEDIATRIC TRANSPLANTATION, 2005, 9 : 118 - 118
  • [2] Valganciclovir as CMV prophylaxis in pediatric transplant recipients.
    Bonatti, H
    Wiesmayr, S
    Junngraithmayr, TC
    Margreiter, R
    Zimmerhackl, LB
    PEDIATRIC TRANSPLANTATION, 2005, 9 : 98 - 98
  • [3] Ganciclovir prophylaxis in CMV high-risk renal transplant recipients.
    Kletzmayr, J
    Safar, T
    Kovarik, J
    Klauser, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A3210 - A3210
  • [4] Ganciclovir vs. valganciclovir for CMV prophylaxis in solitary pancreas transplant recipients.
    Rea, DJ
    Kudva, YC
    Larson, TS
    Stegall, MD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 380 - 380
  • [5] Valgan (ganciclovir hydrochloride) provides ineffective prophylaxis against cytomegaloviral (CMV) infection in liver transplant recipients.
    Jain, A
    Orloff, M
    Lansing, K
    Kashyap, R
    Kelley, M
    Betts, R
    Menegus, M
    Adel, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 569 - 569
  • [6] CMV Disease in Adult Liver Transplant Recipients.
    Griffiths, Ben
    Gane, Ed
    Fitt, Sarah
    Croxson, Kitty
    Munn, Stephen
    LIVER TRANSPLANTATION, 2013, 19 : S223 - S223
  • [7] High rate of symptomatic cytomegaloviral (CMV) infection with valgan (ganciclovir hydrochloride) prophylaxis in post liver transplant recipients.
    Jain, A
    Orloff, M
    Lansing, K
    Kashyap, R
    Kelley, M
    Betts, R
    Menegus, M
    Bozorgzadeh, A
    LIVER TRANSPLANTATION, 2004, 10 (06) : C20 - C20
  • [8] Pre-emptive ganciclovir therapy based on PCR compared with prophylaxis for prevention of CMV disease in high risk liver transplant recipients.
    de Vera, M
    Smallwood, GA
    Davis, L
    Stieber, A
    Thomas, H
    TRANSPLANTATION, 2000, 69 (08) : S407 - S407
  • [9] Randomized trial of oral ganciclovir plus cytomegalovirus (CMV) immune globulin (Ig) versus oral ganciclovir alone for CMV prophylaxis in liver and kidney transplant recipients.
    Johnson, M
    Zacks, S
    McIver, P
    Russo, M
    Dupuis, R
    Andreoni, K
    Gerber, D
    Malat, G
    Salm, J
    Shrestha, R
    Fair, J
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 535 - 535
  • [10] Incidence of CMV with dual therapy prophylaxis in orthotopic liver transplant recipients.
    Ashcraft, EE
    Baillie, GM
    Polito, CC
    Buchanan, EP
    Rodwell, D
    Brown, E
    Rogers, J
    Lin, A
    Baliga, PK
    Chavin, KD
    HEPATOLOGY, 2002, 36 (04) : 661A - 661A
12345